S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
New CBOE “special perk” helps traders target income every weekend (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

ALIOF Stock Price, News & Analysis (OTCMKTS:ALIOF)

$278.50
0.00 (0.00%)
(As of 09/27/2022)
Compare
Today's Range
$278.50
$278.50
50-Day Range
$278.50
$278.50
52-Week Range
$138.01
$286.30
Volume
N/A
Average Volume
924 shs
Market Capitalization
$29.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ALIOF stock logo

About ALIOF Stock (OTCMKTS:ALIOF)

Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.

ALIOF Stock Price History

ALIOF Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive ALIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/16/2015
Today
12/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & Botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ALIOF
CIK
N/A
Employees
N/A
Year Founded
1997

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$29.89 billion
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ALIOF was last updated on Sunday, December 3, 2023 at 4:59 PM.

Pros

Here are some ways that investors could benefit from investing in ALIOF:

  • Recent developments in ALIOF have shown positive growth potential, indicating a promising future for the company.
  • ALIOF's latest product, the ALIOF X, has received positive reviews and is expected to drive sales and revenue.
  • ALIOF's stock price has been steadily increasing over the past year, providing potential for capital appreciation.
  • ALIOF has a strong financial position with a healthy balance sheet and positive cash flow, reducing the risk of financial instability.
  • ALIOF has a diversified product portfolio, reducing reliance on any single product and providing stability in revenue streams.

Cons

Investors should be bearish about investing in ALIOF for these reasons:

  • The competitive landscape in the industry is intense, with several well-established players, which may pose challenges for ALIOF's market share.
  • ALIOF's latest financial reports show a decline in profitability, raising concerns about the company's ability to generate sustainable earnings.
  • The global economic uncertainty and potential market volatility may impact ALIOF's sales and revenue growth.
  • ALIOF's heavy reliance on a single market or region exposes it to geopolitical risks and regulatory changes that could negatively impact its operations.
  • ALIOF's high debt levels may limit its flexibility in pursuing growth opportunities and increase its vulnerability to interest rate fluctuations.














ALIOF Stock Analysis - Frequently Asked Questions

How have ALIOF shares performed in 2023?

ALIOF's stock was trading at $278.50 at the beginning of 2023. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50.
View the best growth stocks for 2023 here
.

How were ALIOF's earnings last quarter?

ALIOF (OTCMKTS:ALIOF) posted its quarterly earnings results on Monday, February, 16th. The company reported $0.87 EPS for the quarter, missing analysts' consensus estimates of $1.09 by $0.22. The firm had revenue of $501.50 million for the quarter, compared to the consensus estimate of $546.30 million.

How do I buy shares of ALIOF?

Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:ALIOF) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -